With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Welcome to cardiology’s jolliest—and most socially acceptable forum—for proving you paid attention to the top news of 2024! Submit your crossword answers, whether you’ve answered all questions or not, ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary ...